QIAGEN NV to acquire Cellesis Limited
QIAGEN NV has reached an agreement to acquire Cellestis Limited for approximately AU$341 million in cash, providing QIAGEN with access to a novel ‘pre-molecular’ technology that offers a new dimension in disease detection not currently possible with other diagnostic methods.
The acquisition of Cellestis will provide QIAGEN with exclusive rights to QuantiFERON technology, a proprietary approach for disease detection and monitoring.
QuantiFERON is complementary to QIAGEN’s portfolio of molecular diagnostics. Its high sensitivity and ability to provide clinically relevant information means that this technology can be used ahead of DNA- or RNA-based molecular testing. Greater use of QuantiFERON technology can help guide and drive the use of traditional DNA- and RNA-based molecular diagnostics.
Horizon Europe negotiations conclude
Once associated, Australian researchers and entities will be able to access Horizon Europe...
AusBiotech responds to Budget 2026–27
The life sciences industry body has responded to measures set out in the Australian...
AI.gov.au launches to help safe and responsible AI use
Providing guidance, tools and resources to help Australian businesses use AI safely, the...
